PT  - JOURNAL ARTICLE
AU  - Adams-Phipps, Jupiter
AU  - Toomey, Danny
AU  - Więcek, Witold
AU  - Schmit, Virginia
AU  - Wilkinson, James
AU  - Scholl, Keller
AU  - Jamrozik, Euzebiusz
AU  - Osowicki, Joshua
AU  - Roestenberg, Meta
AU  - Manheim, David
TI  - A Systematic Review of Human Challenge Trials, Designs, and Safety
AID  - 10.1101/2022.03.20.22272658
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.20.22272658
4099  - http://medrxiv.org/content/early/2022/03/21/2022.03.20.22272658.short
4100  - http://medrxiv.org/content/early/2022/03/21/2022.03.20.22272658.full
AB  - Background There exists no prior systematic review of human challenge trials (HCTs) that focuses on participant safety. Key questions regarding HCTs include how risky such trials have been, how often adverse events (AEs) and serious adverse events (SAEs) occur, and whether risk mitigation measures have been effective.Methods A systematic search of PubMed and PubMed Central for articles reporting on results of HCTs published between 1980 and 2021 was performed and completed by 10/7/2021.Results Of 2,838 articles screened, 276 were reviewed in full. 15,046 challenged participants were described in 308 studies that met inclusion criteria. 286 (92.9%) of these studies reported mitigation measures used to minimize risk to the challenge population. Among 187 studies which reported on SAEs, 0.2% of participants experienced at least one challenge-related SAE. Among 94 studies that graded AEs by severity, challenge-related AEs graded “severe” were reported by between 5.6% and 15.8% of participants. AE data were provided as a range to account for unclear reporting. 80% of studies published after 2010 were registered in a trials database.Conclusions HCTs are increasingly common and used for an expanding list of diseases. Although AEs occur, severe AEs and SAEs are rare. Reporting has improved over time, though not all papers provide a comprehensive report of relevant health impacts. From the available data, most HCTs do not lead to a high number of severe symptoms or SAEs. This study was preregistered on PROSPERO as CRD42021247218.Competing Interest Statement1DaySooner advocates for volunteers in HCTs and supports their broader usage. Several authors of the paper have volunteered for HCTs, though none have participated in a trial. Several authors of the paper were employed by 1DaySooner's research team for this work, which is intended to be independent of the advocacy group. For this reason, there was no review of the manuscript nor input about the results from the management nor from the advocacy team. DM has been paid externally for work with both the advocacy and research teams at 1DaySooner, as well as other related advocacy and policy research. WW provides scientific consulting for pharmaceutical companies and other organizations which conduct clinical trials, but not for HCTs. MR is a professor and the clinical head of the Controlled Human Infection Center at Leiden University, which conducts challenge trials. JO has worked on challenge trials, and is working with an international collaborative group to drive development of a GAS pharyngitis CHIM. EJ has contributed to WHO Ethics Guidance documents on Human Challenge Trials and has received funding from the Wellcome Trust, including current grants 221719 and 216355, which supported work for this paper.Funding StatementThis work was supported by 1Day Sooner. David Manheim was supported by grants from the Center for Effective Altruism's Long Term Future Fund. Euzebius Jamrozik's work was supported by the Wellcome Trust, including current grants 221719 and 216355.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is publicly available online at https://github.com/1DaySooner/HCTSystematicReview